[artículo] 
inPsychiatric Clinics of North America > Año 2015 - Vol.38 No. 3 (Septiembre) . - pp. 379-393

Título :	Development of new psychopharmacological agents for depression and anxiety
Tipo de documento:	texto impreso
Autores:	Alan F. Schatzberg, Autor
Fecha de publicación:	2020
Artículo en la página:	pp. 379-393
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Antidepresivos, Ansiolíticos, Ketamina, Antagonistas de NMDA, Agentes glutamatérgicos, Antagonistas de glucocorticoides, Toxina obotulínica, Agentes opioides Mu
Resumen:	Antidepressant and anxiolytic drug development has largely stalled. This article reviews novel current programs for developing depressants and anxiolytics. Biological bases are discussed for these, as are recent results. Problems encountered are reviewed. Recently announced failed programs for other antidepressants are then discussed with an eye toward uncovering possible common elements that may explain their failures.
Link:	./index.php?lvl=notice_display&id=24199

[artículo] Development of new psychopharmacological agents for depression and anxiety [texto impreso] / Alan F. Schatzberg, Autor . - 2020 . - pp. 379-393.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2015 - Vol.38 No. 3 (Septiembre) . - pp. 379-393

Palabras clave:	Antidepresivos, Ansiolíticos, Ketamina, Antagonistas de NMDA, Agentes glutamatérgicos, Antagonistas de glucocorticoides, Toxina obotulínica, Agentes opioides Mu
Resumen:	Antidepressant and anxiolytic drug development has largely stalled. This article reviews novel current programs for developing depressants and anxiolytics. Biological bases are discussed for these, as are recent results. Problems encountered are reviewed. Recently announced failed programs for other antidepressants are then discussed with an eye toward uncovering possible common elements that may explain their failures.
Link:	./index.php?lvl=notice_display&id=24199